Gelsolin - BioAegis Therapeutics

Drug Profile

Gelsolin - BioAegis Therapeutics

Alternative Names: Gelsolin recombinant; hu r-P gelsolin; pGSN; Recombinant human plasma gelsolin; rh gelsolin; rhu-pGSN; Solinex

Latest Information Update: 10 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Brigham and Womens Hospital
  • Developer BioAegis Therapeutics; Critical Biologics Corporation
  • Class Anti-inflammatories; Antibacterials; Antifibrotics; Antineoplastics; Bronchodilators; Expectorants; Proteins
  • Mechanism of Action Actin inhibitors; Protein replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Community-acquired pneumonia
  • Discontinued Bronchitis; Cystic fibrosis; Systemic inflammatory response syndrome

Most Recent Events

  • 03 Aug 2018 Phase-I/II clinical trials in Community-acquired pneumonia in Australia (IV) (NCT03466073)
  • 24 Jun 2018 Biomarkers information updated
  • 04 Oct 2017 Preclinical pharmacodynamics data in Pneumonia presented at the IDWeek 2017 (IDW-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top